Features
In conversation with
-
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.
-
How LSD and classic psychedelics are re-entering modern psychiatry
Definium’s CMO talks about evaluating psychedelic medicine(s) in the modern era and developing novel treatments for mental health disorders.
-
How human organs are rewriting the rules of drug development
Dr. Jenna DiRito talks about why human organs may represent the “missing chapter” in our understanding of disease, and how this approach is already changing conversations with investors and regulators.
-
How digital twins are pioneering a new era of personalized, longitudinal healthcare
Dr. Amanda Randles explains how they are developing digital twins to move medicine beyond static snapshots to dynamic, personalized care.
-
Why Pharma can’t ignore friendshoring in supply chain
Bora Pharma exec, J.D. Mowery, discusses how geopolitical shifts are reshaping pharmaceutical manufacturing and supply chain strategy.
-
Inside Immunai’s plan to map the entire immune system
Immunai CEO Noam Solomon details four pivotal studies shaping the future of immunology and oncology research, as part of the ‘Grand Collaboration’.
-
How ambient AI is capturing healthcare’s unheard data
The Sciensus team discusses how ambient AI captures patient sentiment to augment nurses, personalise care, and help keep patients healthier at home.
Analysis
-
CAR T enters a new era of in vivo reprogramming of T cells
Vyriad’s Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.
-
Building resilient pharmaceutical supply chains in an era of disruption
Kum Ming Woo advises prioritizing supplier quality & availability over cost, emphasizing geographic diversification and stage-appropriate strategies.
-
Hospital of 2026: Local LLMs and AI Are Redefining Healthcare
myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.
Archive
-
Arkin Bio Ventures III: $100 million fund for transformative therapies
Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.
-
The New Gold Rush: High-stakes race for multi-cancer blood tests
Abbott’s $23 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Meng talks about the major players in the sector and hurdles.
-
Examining the growing delays in clinical trial start-up
ICON exec discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.
-
AI in MedTech: Transforming complaint monitoring
IQVIA’s Mike King on how AI enhances complaint handling, product design, and patient safety.
-
The future of AI in healthcare: Why data quality matters
Dr. Mitesh Rao of OMNY Health explains why high-quality, representative data is the key to AI’s success in healthcare.
-
Inside Immunai’s grand collaboration: Mapping the future of immunology
Immunai CEO Noam Solomon discusses the Grand Collaboration Initiative and the future of immune profiling.
-
Vector BioMed pioneers affordable CAR-T cell therapies in India
The US-based company plans to deliver CAR-T cell therapies at low cost, with the first patients expected to receive therapy in 2026.
-
Building sustainable medical products: Polaroid exec on innovation and challenges
Head of Product at Polaroid Therapeutics, Paul Saunders, shares his approach to embedding sustainability in healthcare innovation.
-
Sustainability by design: Allegro CEO on greener medical innovation
Lucas Decuypere, CEO of the Belgian MedTech company, on making sustainability a core part of medical product design from day one.
-
Precision, not hype: Phenomix CEO on the future of obesity treatment
Mark Bagnall discusses why personalized biology, not just buzz, is key to solving the obesity epidemic.
-
SpotitEarly bets on breath-based cancer detection
US-based startup tests unconventional mix of AI, biochemistry, and trained dogs to identify early-stage cancer through exhaled breath.
-
AI in Pharma: Why regulatory rigor is a catalyst, not a constraint
Ostro CEO Chase Feiger explains how embracing regulation can accelerate AI innovation in life sciences.
-
More regulations needed to increase transparency in sustainability reporting
Swiss CDMO ten23 health’s CEO talks about challenges in sustainability reporting and his approach to environmental sustainability.
-
From Blade Runner to battlefield: US military and BTF plan to assess TBI in seconds
The BTF and MTBI2 are co-developing rapid screening guidelines that could assess traumatic brain injury (TBI) in 90 seconds.
-
US lawmakers propose ban on DTC pharma ads: A call for reform or overreach?
A new bill aims to ban direct-to-consumer (DTC) advertising for prescription drugs in the US.